Lynda K. Ball, MSN, RN, CNN Quality Improvement Director Northwest Renal Network Improving Sub-Optimal Hemoglobins October 14, 2010.

Slides:



Advertisements
Similar presentations
Cardiovascular Disease In CKD: Is It for Children
Advertisements

Dialysis Patient Needs In A Disaster List information On your local / regional meeting And your presenters In this space.
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Network 11 Quality Update Chris Singer, MAN, RN, CNN December 4, 2008.
Dialysis vs Transplant: the Australia & New Zealand experience Stephen McDonald ANZDATA Registry Adelaide, South Australia.
Chronic Uremic Acidosis Nutritional Effects 2 Hypoalbuminemia Osteomalacia (bone mineral loss) Decreased muscle mass Increased incidence of morbidity and.
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
NSAIDs and GI and Renal Complications Lessons from Tennessee Medicaid population studies (and selected others)
Chapter 3: Clinical Indicators and Preventive Care 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Finnish Registry of Kidney Disease, FRKD Quality Registries Meeting Stockholm, December 8th-9th, 2014 presented by: Carola Grönhagen-Riska (chair of the.
Chapter 2: Healthy People A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Wisconsin Pressure Ulcer Coalition Data Update Outcomes Congress Nathan Williams Jody Rothe, RN, WCC December 2, 2009.
Chapter 12: USRDS Special Study Center on Transition of Care in CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.
Dialysis Facility Compare Valarie Ashby Co-Managing Director UM-KECC.
UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.
Chapter 5: Mortality 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Feast or Famine: Survival and Chronic Kidney Disease Kerin Worley and Deb Gipson UNC Chapel Hill April, 2004.
I will not discuss off label use and/or investigational use in my presentation. I have financial relationships to disclose: Employee of: Fresenius Medical.
Dialysis Patient Needs In A Disaster. CMS Disclaimer: This presentation was developed by Northwest Renal Network while under contract with the Centers.
Dialysis: outcome and complications. Introduction Outcomes – 20%+ of dialysis patients die each year, 3YS diabetics ~50% Technical complications –PD –Haemo.
Review of literature and report of experience with erythropoietin in ESRD populations Summary to FDA Cardio Renal Committee J. Michael Lazarus, M.D. CMO.
Dialysis Outcomes and Practice Patterns Study Impact of Dialysis Prescriptions and Practices on Outcomes Friedrich K. Port, MD, MS Arbor Research Collaborative.
Maximizing HHQI Resources to Reduce Readmissions: Part 2 Presented by Cindy Sun, HHQI RN Project Coordinator.
Cannulation of the Arteriovenous Fistula (AVF) Lynda K. Ball, RN, BSN, CNN Quality Improvement Director Northwest Renal Network Seattle, Washington Activity.
A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 6: Mortality.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 14: End-of-life Care for Patients with End-Stage Renal Disease:
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 10: Dialysis Providers.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 2: Healthy People 2020.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Similar Outcomes With Hemodialysis and Peritoneal.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Has Public Reporting of Hospital Readmission Rates.
USRDS USRDS 2002 adr Incident counts by initial modality figure 7.1 patients age 19 years & younger.
Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015
2016 Annual Data Report, Vol 2, ESRD, Ch 6
Figure 10.1 Dialysis unit counts, by unit affiliation, 2011–2014
First-year death rates by modality figure 8
Volume 2: End-Stage Renal Disease
Volume 2: End-Stage Renal Disease
December 31st point prevalent counts by modality figure 3.1
2016 Annual Data Report, Vol 2, ESRD, Ch 4
Hospital admissions per patient, by modality figure 5
Chapter 2: Clinical Indicators and Preventive Care
Mortality HRs for dialysis modality (PD versus HD) in 23,718 incident dialysis patients using a marginal structural model (MSM) taking into account changes.
Independent and Joint Associations of Nutritional Status Indicators With Mortality Risk Among Chronic Hemodialysis Patients in the Dialysis Outcomes and.
Adjusted all-cause mortality risk by dialysate sodium (DNa) and predialysis serum sodium (SNa). Adjusted all-cause mortality risk by dialysate sodium (DNa)
New options for the anemia of chronic kidney disease
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Volume 2: End-Stage Renal Disease
Volume 2: End-Stage Renal Disease
Volume 85, Issue 1, Pages (January 2014)
Volume 68, Issue 6, Pages (December 2005)
Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns.
Iain C. Macdougall, MD  American Journal of Kidney Diseases 
Volume 86, Issue 4, Pages (October 2014)
This Month in AJKD American Journal of Kidney Diseases
Volume 67, Issue 3, Pages (March 2005)
Volume 85, Issue 1, Pages (January 2014)
Manish M. Tanna, MD, Edward F. Vonesh, PhD, Stephen M. Korbet, MD 
Volume 70, Issue 10, Pages (November 2006)
The Use of Vaccines in Adult Patients With Renal Disease
Pediatric in-center hemodialysis patients
Collecting and using patient and treatment center data to improve care: Adequacy of hemodialysis and end-stage renal disease surveillance1  William M.
E.F. Vonesh, J.J. Snyder, R.N. Foley, A.J. Collins 
Adjusted hazard ratio (AHR) of final AVF failure by percent consistent facility aspirin use. Adjusted hazard ratio (AHR) of final AVF failure by percent.
Among three residual kidney function (RKF) indices, only residual urine volume (UV) indicated an independent prognostic value in patients with UV≥0.1 or.
Associations of dialysis session length with mortality and hospitalizations. Associations of dialysis session length with mortality and hospitalizations.
Risk of mortality in patients with diabetes and ESRD
Survival among hemodialysis patients by geographic region in DOPPS 3 (2005–2008), with and without adjustments for patient mix differences. Survival among.
Mortality risk by age at study entry across DOPPS regions.
Presentation transcript:

Lynda K. Ball, MSN, RN, CNN Quality Improvement Director Northwest Renal Network Improving Sub-Optimal Hemoglobins October 14, 2010

This presentation was developed by Northwest Renal Network while under contract with the Centers for Medicare & Medicaid Services, Baltimore, Maryland, Contract #HHSM NW016C. The contents presented do not necessarily reflect CMS policy.

RR of Hospitalization Higher Patient Hemoglobin Values Associated with Lower Risk of Hospitalization p< p=0.05 p=0.77 (Ref) Patient Hemoglobin, g/dL p=0.001 Overall RR = 0.94 (p < ) per 1 g/dL higher hemoglobin (n=435)(n=2484)(n=1994)(n=1789)(n=1296) DOPPS I: 7 countries, patients on dialysis > 180 days, adjusted for age, gender, black race, 15 comorbid classes, spktv,serum PO 4, serum calcium, albumin, country, facility clustering. Pisoni et al AJKD 44, (2004)

RR of Death Higher Hemoglobin Levels Associated with Lower Mortality Risk p=0.04p=0.08 Ref. Patient Hemoglobin, g/dL p=0.34 Overall RR = 0.95 (p = 0.003) per 1 g/dL higher hemoglobin DOPPS I: 7 countries, patients on dialysis > 180 days, adjusted for age, gender, black race, 15 comorbid classes, spktv,serum PO 4, serum calcium, albumin, country, facility clustering. Pisoni et al AJKD 44, (2004) (n=506) (n=2740) (n=2202) (n=1403) (n=1936) p=0.19

Lower Mortality Risk (RR of death=0.90 for every 1 g/dL higher facility mean Hgb concentration, p=0.02) DOPPS I: 7 countries, adjusted for age, gender, black race, 15 comorbid classes, spktv,serum PO 4, serum calcium, albumin, country, and facility clustering. Pisoni RL et al. AJKD, 44: (2004)

Large improvement in mean Hgb in US from In 2002, 27% of US HD patients had a Hgb <11 g/dL New ESRD patients in US: much lower Hgb values (10.4 g/dL) at time of starting HD compared with prevalent HD patients (11.7 g/dL) Predictors of having a higher Hgb include: ~ higher albumin ~ higher TSAT ~ not using a catheter for vascular access ~ higher country mean EPO dose Higher Hgb levels are associated with significantly lower mortality and hospitalization risks

Patient Factors Diabetes ESA Deficiency RBC Lifespan SHPT Iron Status Co- Morbidities

Intercurrent Issues Infection/ Inflammation Hospitalization Vascular Access Events Catheters New to Dialysis (1 st 90 days) Blood Loss Kausz et al., AJKD, 45, 2005

IT TAKES APPROXIMATELY 6 MONTHS AFTER INITIATION OF DIALYSIS TO ACHIEVE Hb > 11 g/DL Hemodialysis Peritoneal dialysis Months after initiation of dialysis Average HB (g/dL) USRDS 2003

Post-hospitalization Hb (g/dL) Before Hospitalization 1 month2 months p<0.001 Hb Levels May Remain Below the NKF- DOQI Target for at Least 2 Months After Each Hospitalization p<0.01 Yaqub. AJ Nephrol 2001, 21:30-396

Practice Patterns Protocol Design KDOQI Hgb Targets CMS Reimbursement Protocol Compliance KDOQI Iron Targets Lab Sampling

New Patients Vascular Access Choice Post-Hospitalization Patients Patients with Co-Morbidities

10 g/dL 12 g/dL  Tight range  Variability from many sources

 The dialysis facility must develop, implement, maintain, and evaluate an effective, data-driven QAPI program with participation of the members of the interdisciplinary team.  It must focus on indicators related to improved health outcomes, and the prevention and reduction of medical errors. For more info...

 Quality Incentive Program (QIP) for dialysis services—the first pay for performance program in fee-for-service—that will link a facility’s payment to how well it meets new performance standards.  The % of Medicare patients with hemoglobins less than 10 g/dL is one of three elements for the Quality Incentive Program (QIP, Medicare Improvements for Patients and Providers Act of 2008 [MIPPA 153c]).  The QIP will take effect on Jan. 1, 2012.

Lynda K. Ball, MSN, RN, CNN Quality Improvement Director x 111